Pheochromocytomas and Paragangliomas as Causes of Endocrine Hypertension
Open Access
- 4 June 2019
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 10, 333
Abstract
Chromaffin tumors are included among the causes of secondary hypertension because of the release of catecholamines. Nevertheless, the clinical, cardiovascular, and hypertensive picture of patients affected by pheochromocytomas/paragangliomas (PPGL) is extremely variable, due to the different quantitative and qualitative releasing activity of these tumors. A consistent percentage of these patients, about 20%, is normotensive and not affected by the characteristic symptomatic crises due to sudden release of catecholamines. The factors causing such wide clinical variability are many and probably not all known. It is well known that many of these tumors are genetically determined and that the genetic profile influences the biochemical characteristics and the biology of the tumors as well as the clinical presentation of the affected patients. The number of asymptomatic or poorly symptomatic patients is increased after the introduction of genetic screening and the early diagnosis in mutation carriers. In this paper we can review the genotype-phenotype correlation of PPGLs with a focus on the cardiovascular picture.Keywords
This publication has 21 references indexed in Scilit:
- Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneityNature Reviews Cancer, 2014
- Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation statusEuropean Journal of Cancer, 2012
- Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paragangliomaHuman Molecular Genetics, 2011
- Catecholamine metabolomic and secretory phenotypes in phaeochromocytomaEndocrine-Related Cancer, 2010
- The Protean Manifestations of PheochromocytomaHormone and Metabolic Research, 2009
- Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytomaEndocrine-Related Cancer, 2008
- Management and Treatment of Pheochromocytomas and ParagangliomasAnnals of the New York Academy of Sciences, 2006
- Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptorsNature, 2004
- Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical PhenotypesThe Journal of Clinical Endocrinology & Metabolism, 2001
- Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical PhenotypesThe Journal of Clinical Endocrinology & Metabolism, 2001